• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Praxis Precision Medicines Inc. (Amendment)

    2/14/24 12:21:52 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRAX alert in real time by email
    SC 13G/A 1 sc13ga_praxis.htm SC 13G/A

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*

    Praxis Precision Medicines, Inc.

    (Name of Issuer – as specified in its charter)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    74006W207

    (CUSIP Number)

    December 31, 2023

    (Date of Event which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    þ       Rule 13d-1(b)

    ¨        Rule 13d-1(c)

    ¨        Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 

     
     

     

    1

    NAME OF REPORTING PERSON

    Eventide Asset Management, LLC

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    ¨ (a)

    ¨ (b)

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

    5

    SOLE VOTING POWER

    0

     

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

     

    8

    SHARED DISPOSITIVE POWER

    0

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.0%

     

    12

    TYPE OF REPORTING PERSON

    IA

           

     

     
     

     

    1

    NAME OF REPORTING PERSON

    Finny Kuruvilla, M.D. Ph. D.

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    ¨ (a)

    ¨ (b)

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

    5

    SOLE VOTING POWER

    0

     

    6

    SHARED VOTING POWER

    0

     

    7

    SOLE DISPOSITIVE POWER

    0

     

    8

    SHARED DISPOSITIVE POWER

    0

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.0%

     

    12

    TYPE OF REPORTING PERSON

    IN;HC

           

     

     
     

     

    1

    NAME OF REPORTING PERSON

    Robin C. John

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    ¨ (a)

    ¨ (b)

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

    5

    SOLE VOTING POWER

    0

     

    6

    SHARED VOTING POWER

    0

     

    7

    SOLE DISPOSITIVE POWER

    0

     

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.0%

     

    12

    TYPE OF REPORTING PERSON

    IN;HC

           

     

     
     

    Item 1. (a) Name of Issuer:

    Praxis Precision Medicines, Inc. (the “Issuer”)

    (b) Address of Issuer’s Principal Executive Offices:

    99 High Street, 30th Floor, Boston, Massachusetts, 02110

    Item 2. (a) Name of Persons Filing:

    (i) Eventide Asset Management, LLC (“Eventide”)

    (ii) Finny Kuruvilla, M.D., Ph.D. (“Kuruvilla”)

    (iii) Robin C. John (“John”)

    (b). Address of Principal Business Office or, if none, Residence:

    Eventide, Kuruvilla and John:

    One International Place, Suite 4210

    Boston, Massachusetts 02110

    (c). Citizenship or Place of Organization:

    Eventide: Delaware

    Kuruvilla: United States

    John: United States

    (d). Title of Class of Securities:

    Common Stock, par value $0.0001 per share

     

    (e). CUSIP Number:

    74006W207

    Item 3. If this statement is filed pursuant to sections 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    (a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

    (b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

    (c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

    (d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

    (e) [x] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E);

    (f) [ ] An employee benefit plan or endowment fund in accordance with section 240.13d- 1(b)(1)(ii)(F);

    (g) [x] A parent holding company or control person in accordance with section 240.13d- 1(b)(1)(ii)(G);

    (h) [ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance

    Act (12 U.S.C. 1813);

    (i) [ ] A church plan that is excluded from the definition of an investment company under

     
     

            section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

    (j) [ ] A non-U.S. institution in accordance with section 240.13d-1(b)(1)(ii)(J);

    (k) [ ] A group, in accordance with section 240.13d-1(b)(1) (ii)(K).

    If filing as a non-U.S. institution in accordance with section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: __________

    Item 4. Ownership:

    Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

    (a). Amount beneficially owned:

    (i) Eventide: 0

    (ii) Kuruvilla: 0

    (iii) John: 0

    (b). Percent of class:

    (i) Eventide: 0.0%

    (ii) Kuruvilla: 0.0%

    (iii) John: 0.0%

    (c). Number of shares as to which the person has:

    (i)        Sole power to vote or to direct the vote:

    (1) Eventide: 0

    (2) Kuruvilla: 0

    (3) John: 0

    (ii)        Shared power to vote or to direct the vote:

     

    (1) Eventide: 0

    (2) Kuruvilla: 0

    (3) John: 0

    (iii) Sole power to dispose or to direct the disposition of:

    (1) Eventide: 0

    (2) Kuruvilla: 0

    (3) John: 0

    (iv) Shared power to dispose or to direct the disposition of:

    (1) Eventide: 0

    (2) Kuruvilla: 0

    (3) John: 0

     
     

    Item 5. Ownership of Five Percent or Less of a Class:

    This statement is being filed to report the fact that as of the date hereof Eventide Asset Management, LLC has ceased to be the beneficial owner of more than five percent of the Issuer’s outstanding Common Stock.

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person:

    Not Applicable

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company:

    Not Applicable

    Item 8. Identification and Classification of Members of the Group:

    Not Applicable

    Item 9. Notice of Dissolution of Group:

    Not Applicable

    Item 10. Certification: 

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    In accordance with Rule 13d-4 of the Securities Exchange Act of 1934, each of the persons filing this statement expressly disclaim the beneficial ownership of the securities covered by this statement and the filing of this report shall not be construed as an admission by such persons that they are the beneficial owners of such securities.

     
     

    SIGNATURES

     

    The undersigned certify, after reasonable inquiry and to the best knowledge and belief of the undersigned, that the information set forth in this Statement is true, complete and correct. The undersigned agree to the filing of this single Statement on Schedule 13G.

     

    Eventide Asset Management, LLC

    Date: February 14, 2024

    By: /s/ Peter J. Luiso

    Name: Peter J. Luiso

    Title: General Counsel

     

    Finny Kuruvilla, M.D., Ph. D.

    Date: February 14, 2024

    By: /s/ Finny Kuruvilla, M.D., Ph. D.

    Name: Finny Kuruvilla, M.D., Ph. D.

    Robin C. John

    Date: February 14, 2024

    By: /s/ Robin C. John

    Name: Robin C. John

     
     

    EXHIBIT 1

    WHEREAS, in accordance with Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934 (the "Act"), only one joint Statement and any amendments thereto need to be filed whenever one or more persons are required to file such a Statement or any amendments thereto pursuant to Section 13(d) of the Act with respect to the same securities, provided that said persons agree in writing that such Statement or amendments thereto is filed on behalf of each of them;

    NOW, THEREFORE, the parties hereto agree as follows:

    Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph. D. and Robin C. John do hereby agree, in accordance with Rule 13d-1(k)(1) under the Act, to file a Statement on Schedule 13G relating to their ownership of the Common Stock of the Issuer, and do hereby further agree that said Statement on Schedule 13G shall be filed on behalf of each of them.

     

    Eventide Asset Management, LLC

    Date: February 14, 2024

    By: /s/ Peter J. Luiso

    Name: Peter J. Luiso

    Title: General Counsel

     

    Finny Kuruvilla, M.D., Ph. D.

    Date: February 14, 2024

    By: /s/ Finny Kuruvilla, M.D., Ph. D.

    Name: Finny Kuruvilla, M.D., Ph. D.

    Robin C. John

    Date: February 14, 2024

    By: /s/ Robin C. John

    Name: Robin C. John

    Get the next $PRAX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRAX

    DatePrice TargetRatingAnalyst
    2/2/2026$282.00Equal Weight
    Wells Fargo
    12/15/2025$250.00 → $750.00Outperform
    Oppenheimer
    11/19/2025$424.00Buy
    BTIG Research
    6/2/2025$97.00Outperform
    Oppenheimer
    5/7/2025$80.00Buy
    Chardan Capital Markets
    3/3/2025$120.00 → $105.00Buy
    H.C. Wainwright
    2/11/2025$111.00Buy
    Deutsche Bank
    8/5/2024$134.00Outperform
    Oppenheimer
    More analyst ratings

    $PRAX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Praxis Precision Medicines Inc.

    SCHEDULE 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

    2/12/26 9:15:03 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Praxis Precision Medicines Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K/A - Praxis Precision Medicines, Inc. (0001689548) (Filer)

    2/10/26 4:52:49 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Praxis Precision Medicines Inc.

    SCHEDULE 13G - Praxis Precision Medicines, Inc. (0001689548) (Subject)

    2/5/26 1:36:41 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRAX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Desimone Jill bought $25,375 worth of shares (14,500 units at $1.75) (SEC Form 4)

    4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)

    10/10/23 7:41:39 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Praxis Precision Medicines with a new price target

    Wells Fargo initiated coverage of Praxis Precision Medicines with a rating of Equal Weight and set a new price target of $282.00

    2/2/26 6:51:57 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer reiterated coverage on Praxis Precision Medicines with a new price target

    Oppenheimer reiterated coverage of Praxis Precision Medicines with a rating of Outperform and set a new price target of $750.00 from $250.00 previously

    12/15/25 11:26:49 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on Praxis Precision Medicines with a new price target

    BTIG Research initiated coverage of Praxis Precision Medicines with a rating of Buy and set a new price target of $424.00

    11/19/25 8:58:01 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Arbuckle Stuart A was granted 1,166 shares (SEC Form 4)

    4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)

    2/10/26 4:59:33 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kindler Jeffrey B was granted 1,166 shares (SEC Form 4)

    4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)

    2/10/26 4:57:40 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Principal Accounting Officer Mastrocola Lauren covered exercise/tax liability with 344 shares, decreasing direct ownership by 2% to 13,446 units (SEC Form 4)

    4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)

    1/13/26 8:20:33 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences

    BOSTON, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report its financial results for the fourth quarter and full year ended December 31, 2025, and provide a corporate update before the financial markets open on Thursday, February 19, 2026. The Company will host a conference call and a live webcast to review the fourth quarter financial results and provide a corporate update on Thursday, February 19, 2026, at 8:00 am ET, which can be accessed by visiting this registration link. The live webcast will also be available on the

    2/9/26 4:01:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on February 2, 2026, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 2,964 shares of its common stock to eight new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4). T

    2/4/26 4:01:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy

    BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced the appointment of world-renowned neurologist and epilepsy authority Dr. Orrin Devinsky, M.D., as Head of Clinical Strategy, a newly created leadership role. Dr. Devinsky is widely regarded as one of the most influential physician-scientists of his generation in modern epilepsy and clinical neuroscience. Over a career spanning more than four decades, he has shaped the development of multiple transformative therapies, built enduring global research initiatives, and helped define t

    1/13/26 4:30:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRAX
    Financials

    Live finance-specific insights

    View All

    Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences

    BOSTON, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report its financial results for the fourth quarter and full year ended December 31, 2025, and provide a corporate update before the financial markets open on Thursday, February 19, 2026. The Company will host a conference call and a live webcast to review the fourth quarter financial results and provide a corporate update on Thursday, February 19, 2026, at 8:00 am ET, which can be accessed by visiting this registration link. The live webcast will also be available on the

    2/9/26 4:01:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results

    RADIANT study with vormatrigine in focal onset seizure (FOS) patients over eight weeks demonstrated 56.3% median reduction in seizure frequency from baseline, with 22% at 100% seizure reduction in last 28 days Initiated two registrational studies for Developmental and Epileptic Encephalopathies (DEEs) programs: EMERALD for broad DEEs with relutrigine and EMBRAVE3 for SCN2A Gain-of-Function (GoF) with elsunersen Relutrigine granted U.S. FDA Breakthrough Therapy Designation for the treatment of seizures associated with SCN2A and SCN8A DEEs, enabling expedited development Cash and investments of approximately $447 million as of June 30, 2025 maintains runway into 2028 Praxi

    8/4/25 8:30:00 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients with Focal Onset Seizures from the RADIANT Study of Vormatrigine

    Dosing with vormatrigine over 8 weeks led to 56.3% median reduction in seizure frequency Approximately 22% of patients reached 100% reduction in seizure frequency in the last 28 days on treatment Rapid and sustained response, with over 54% of patients achieving 50% response in the first week Vormatrigine was generally well tolerated and continues to demonstrate favorable safety profile BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitati

    8/4/25 8:00:00 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Praxis Precision Medicines Inc.

    SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

    11/14/24 7:53:30 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Praxis Precision Medicines Inc.

    SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

    11/14/24 5:50:15 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Praxis Precision Medicines Inc.

    SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

    11/14/24 5:46:12 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRAX
    Leadership Updates

    Live Leadership Updates

    View All

    Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy

    BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced the appointment of world-renowned neurologist and epilepsy authority Dr. Orrin Devinsky, M.D., as Head of Clinical Strategy, a newly created leadership role. Dr. Devinsky is widely regarded as one of the most influential physician-scientists of his generation in modern epilepsy and clinical neuroscience. Over a career spanning more than four decades, he has shaped the development of multiple transformative therapies, built enduring global research initiatives, and helped define t

    1/13/26 4:30:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments

    BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation–inhibition imbalance, today announced the appointment of Jeffrey B. Kindler and Stuart Arbuckle to its board of directors, and the promotions of Megan Sniecinski to Chief Operating Officer and Dr. Steven Petrou to President of Research & Development. "These leadership decisions reflect a deliberate evolution of Praxis as we enter a phase driven by commercial launch planning and execution readiness, late-stage developm

    1/8/26 4:45:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2022 Financial Results

    PRAX-944 Phase 2b Essential1 Study topline results expected in 4Q22; primary endpoint updated to efficacy PRAX-562 Phase 1 study completed, confirming biomarker change and potential for wide therapeutic window Cash and investments of $165.4 million as of June 30, 2022 supports runway into 1Q24 BOSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update and reported financial results for the second quarter of 2022

    8/8/22 4:01:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care